Published online Apr 21, 2014. doi: 10.3748/wjg.v20.i15.4414
Revised: October 27, 2013
Accepted: January 8, 2014
Published online: April 21, 2014
Processing time: 224 Days and 13 Hours
AIM: To assess whether differential expression of caspase-3 in paired metastatic lymph nodes (LNs) is prognostic of survival in patients with resectable esophageal squamous cell carcinoma (ESCC).
METHODS: Capases-3 expression was evaluated immunohistochemically in 122 pairs of primary ESCCs and regional metastatic LNs assembled on tissue microarrays. The impact of caspase-3 expression on survival outcomes was analyzed by the Kaplan-Meier method and Cox proportional hazards regression model.
RESULTS: The level of caspase-3 expression was significantly higher in LN metastases than in primary tumors (P < 0.001). Caspase-3 expression in the primary tumors was associated with longer median survival (23 mo vs 21 mo, P = 0.033), whereas higher expression in paired metastatic LNs was associated with shorter median survival (20 mo vs 22 mo, P = 0.043). Multivariate analysis showed that both were independent prognostic factors.
CONCLUSION: Caspase-3 expression in metastatic LNs may be a potential independent predictor of poorer overall survival in patients with resected ESCC and LN metastasis. Protein expression in metastatic tumors may be a biomarker prognostic of survival.
Core tip: Reduced caspase-3 expression in primary esophageal squamous cell carcinoma (ESCC) is associated with poorer outcomes, but the prognostic value of caspase-3 in metastatic lymph nodes (MLNs) is unclear. Analysis of 122 patients with primary ESCCs and paired MLNs showed that higher caspase-3 expression in MLNs from ESCC was associated with poorer prognosis. To the best of our knowledge, this study is the first to report the potential prognostic value of caspase-3 expression in MLNs of ESCC. Additional studies are needed to assess the prognostic importance of this biomarker.